Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Financing cash flow of -$556K in Q2 FY2026

Q2 FY2026 financing cash flow was -$556K.

Context

  • Financing cash flow amounted to 10519.4% of revenue in FY2025.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$556K-55.2% QoQ
Last fiscal yearDec 2025
$142.01M+71.6% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+71.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
142.01M USD
Year-over-year change
+71.6%
1-year CAGR
+71.6%

Financing Cash Flow vs competitors

How ATTO compares with its peers on the latest reported figures

  • ATTO's FY2025 financing cash flow of $142.01M is the 4th largest of the 10 companies compared; the peer median is $103.52M.
  • Its year-over-year change of +71.6% is the 4th highest of 9, against a peer median of +47.0%.
  • Financing cash flow amounts to 10519.4% of revenue for ATTO, versus a peer median of 1165.8%.
ATTO Competitors Peer median
Financing Cash Flow for ATTO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ORKAOruka Therapeutics, Inc.LTM Sep 2026$830.71M +390.1%——
ALMSAlumis Inc. Common StockLTM Jun 2026$360.93M +53.0%-72.7%4878.8%
EVMNEvommune, Inc.LTM Mar 2026$338.03M ——3380.3%
ATTOAttovia Therapeutics, Inc.FY2025$142.01M +71.6%—10519.4%
ZURAZura Bio LimitedLTM Mar 2026$127.78M +11.1%——
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$103.52M +40.9%+6.8%—
ANABAnaptysBio, Inc.LTM Mar 2026$102.81M -191.7%—44.2%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$52.19M -29.8%—623.8%
QTTBQ32 Bio Inc.LTM Mar 2026$5.67M +234.8%—10.6%
CNTBConnect Biopharma Holdings LimitedFY2025$1.09M +381.5%—1707.8%
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding ATTO) $103.52M+47.0%-32.9%1165.8%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.